Positive Eroxon® & Eroxon® “Intense” HUT results
Summary by AI BETAClose X
23 March 2026
Futura Medical plc
("Futura" or the "Company")
Positive results from Eroxon® & new Eroxon® "Intense" Home User Test
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to report the results of the Home User Test ("HUT") conducted on the current Eroxon® product and prototype product Eroxon® 'Intense' ("Intense").
The results of the HUT are positive (with an overall improvement on the original Phase 3 study for Eroxon®) and give the Company confidence that the Intense formula gives a statistically significant greater sensorial effect over the current Eroxon® formulation especially in the first two minutes after application.
Home User Test results summary
The study compared the new Intense formula with current Eroxon® over 4 weeks in 223 subjects (112 tested Eroxon® and 111 tested Intense). Subjects were based in the United Kingdom and were recruited on-line. Each subject was individually interviewed to assess their suitability for inclusion into the study. Subjects were male, 18-59 years of age and 94% assessed as suffering from mild to moderate erectile dysfunction ("ED").
In this selected demographic, both Eroxon® and Intense were judged to have high efficacy rates. Subjects stated that they were satisfied with the hardness of their erection in 70% and 71% of their sexual encounters using Eroxon® or Intense, respectively. Subjects also recorded that their erections lasted long enough to have sexual intercourse in 84% and 85% of encounters, respectively.
Using the clinically validated and most widely used measure of erection functionality (the IIEF-EF scale*), subjects in both groups showed a highly significant and clinically important improvement in their erectile function. The improvement versus baseline (pre-treatment) was at least as good as reported in the Phase 3 clinical study FM71, which was used to obtain regulatory approval in the US.
The study also showed that when either Eroxon® or Intense was applied onto the study participant by their partner it increased effectiveness and showed significantly higher erection maintenance.
The study confirmed the sensorial enhancement of Intense over Eroxon® with statistically significant greater intensity during the first two minutes after application.
Additionally, both products were well tolerated in men and their female partners.
Both formulations received favourable 4- or 5-star ratings in 49% and 53% of subjects for Eroxon® and the Intense formula respectively. Over 50% of study participants said they would be somewhat or very likely to purchase either product.
In summary, the HUT study confirmed that a more targeted approach of marketing to consumers under 60 years of age with mild to moderate ED will likely lead to higher efficacy and satisfaction rates and thus higher in-market repeat purchase rates. Encouraging users to use the product with their partners as part of foreplay will likely also improve the overall product experience. The Intense formula will appeal to those consumers seeking a more rapid or stronger sensorial effect, especially in younger age groups. Detailed work is now underway to assess and update optimal brand positioning. Meanwhile, data necessary to support regulatory filings for Eroxon® Intense in Europe and USA has been generated and a "Special" 510K submission has been filed with the US FDA. Regulatory authorisation in the US and Europe is expected in H1 2026.
* Rosen, Riley, Wagner, Osterloh, Kirkpatrick and Mishra. Urology. Volume 49, Issue 6, June 1997, pages 822-830
Ken James, Executive Director and Head of R&D commented: "We are very pleased to report this positive data for Eroxon® and Eroxon® Intense, and ease of use in a real‑world setting. These findings provide further validation of our formulation science and give us confidence as we progress Eroxon® Intense through regulatory authorisation and build an optimal brand position."
Contacts:
|
Futura Medical plc
|
Alexander Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
|
investor.relations@futuramedical.com +44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Turner Pope Investments (TPI) Ltd Broker |
Guy McDougall, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0)20 3405 0205 |
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to date. Multiple distribution partnership agreements are in place for Eroxon, across major consumer markets.
WSD4000 is a prototype product platform designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 products have the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund